
Healthcare · BSE
Speciality Medicines Limited was incorporated in 2021 and focuses on marketing and distributing speciality pharmaceutical medicines, including expensive oral and injectable drugs used to treat serious and long-term health conditions in both Indian and international markets. The company offers many types of finished pharmaceutical products in different forms such as tablets, capsules, creams, syrups, eye drops, gels, injections, inhalers, nasal sprays, ointments, sachets, and suspensions. It operates through two main models: contract manufacturing of finished medicines for international markets and marketing and distribution of speciality medicines sourced from other manufacturers. The company has expanded globally with products registered or under registration in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia, and its distribution network covers more than 20 states in India and over 35 countries worldwide. As of March 31, 2025, one product was registered overseas and 60 products were under registration in five countries, contributing to revenue, and as of August 31, 2025, the company had 18 permanent employees working in different departments.
Price Band
₹117 – ₹124
Issue Size
₹235.00 L Cr
Lot Size
1000 shares
GMP
Est. Listing
₹124
at current GMP
Subscribed
2.33x
overall
Open
20 Mar 2026
Close
24 Mar 2026
Allotment
25 Mar 2026
Refund
26 Mar 2026
Demat Credit
27 Mar 2026
Listing
30 Mar 2026
Last updated: 30 Mar 2026
Current Premium
Issue Price (Upper)
₹124
Band: ₹117 – ₹124
Estimated Listing Price
₹124
Upper price + GMP
Lot Size
1000 shares
Min investment ₹1,24,000
Estimated Profit / Lot
₹0
1000 × ₹0
Grey Market Premium trend
—
▲ 0 today
Updated 1 minute ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 27 Sep 2026 | — | 0.0% | ₹124 |
| 26 Sep 2026 | — | 0.0% | ₹124 |
| 25 Sep 2026 | — | 0.0% | ₹124 |
GMP is unofficial market data. Not a guarantee of listing performance.
Speciality Medicines Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹23,50,000 Crores. The shares are offered at a price band of ₹117 to ₹124 per equity share on BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Following the close of bidding on 2026-03-24, the basis of allotment is scheduled to be finalized on 2026-03-25. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Skyline Financial Services Private Limited) or the BSE allotment checking window.
The latest grey market premium for Speciality Medicines Limited IPO is ₹0, which indicates an expected listing price of ₹124.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.